{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:35:53Z","timestamp":1771472153068,"version":"3.50.1"},"reference-count":18,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,3]]},"abstract":"<jats:p>rVSV\u0394G-ZEBOV-GP vaccine is a live recombinant (r) vesicular stomatitis virus (VSV), where the VSV G protein is replaced with the Zaire Ebola virus (ZEBOV) glycoprotein (GP). For vaccine immunogenicity testing, clinical trial sera collected during an active ZEBOV outbreak underwent gamma irradiation (GI) before testing in biosafety level 2 laboratories to inactivate possible wild-type ZEBOV. Before irradiating pivotal trial samples, two independent studies evaluated the impact of GI (50 kGy) on binding ZEBOV-GP (ELISA) antibodies against rVSV\u0394G-ZEBOV-GP, using sera from a North American phase 1 study. Gamma irradiation was associated with slightly higher antibody concentrations in pre-vaccination samples and slightly lower concentrations postvaccination. Results indicate that GI is a viable method for treating samples from regions where filoviruses are endemic, with minor effects on antibody titers. The impact of GI on immunogenicity analyses should be considered when interpreting data from irradiated specimens.<\/jats:p>","DOI":"10.4269\/ajtmh.19-0076","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T07:39:41Z","timestamp":1559633981000},"page":"207-213","source":"Crossref","is-referenced-by-count":14,"title":["Effect of Gamma Irradiation on the Antibody Response Measured in Human Serum from Subjects Vaccinated with Recombinant Vesicular Stomatitis Virus\u2013Zaire Ebola Virus Envelope Glycoprotein Vaccine"],"prefix":"10.4269","volume":"101","author":[{"given":"Rebecca J.","family":"Grant-Klein","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Antonello","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Nichols","sequence":"additional","affiliation":[{"name":"Crozet BioPharma, Devens, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri","family":"Dubey","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Simon","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"b1","series-title":"PLoS Pathog","first-page":"e1003467","article-title":"Emerging infectious diseases: threats to human health and global stability","volume":"9","author":"Morens","year":"2013"},{"key":"b2","series-title":"J Infect Dis","first-page":"S218","article-title":"Inactivation of Zaire ebolavirus variant Makona in human serum samples analyzed by enzyme-linked immunosorbent assay","volume":"214","author":"Cutts","year":"2016"},{"key":"b3","series-title":"Guidance on the Inactivation or Removal of Select Agents and Toxins for Future Use","author":"Centers for Disease Control and Prevention, Division of Select Agents and Toxins, Animal and Plant Health Inspection Service, Agricultural Select Agent Program","year":"2017"},{"key":"b4","series-title":"N Engl J Med","first-page":"1647","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016"},{"key":"b5","series-title":"CMAJ","first-page":"E819","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial","volume":"189","author":"ElSherif","year":"2017"},{"key":"b6","series-title":"N Engl J Med","first-page":"330","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017"},{"key":"b7","series-title":"Lancet Infect Dis","first-page":"854","article-title":"Safety and immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017"},{"key":"b8","series-title":"Lancet Infect Dis","first-page":"1156","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015"},{"key":"b9","series-title":"Lancet","first-page":"505","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ca suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017"},{"key":"b10","series-title":"N Engl J Med","first-page":"1438","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017"},{"key":"b11","series-title":"J Infect Dis","first-page":"S6","article-title":"The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSV\u0394G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak","volume":"217","author":"Samai","year":"2018"},{"key":"b12","series-title":"J Infect Dis","first-page":"1789","article-title":"Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017"},{"key":"b13","series-title":"J Clin Microbiol","first-page":"704","article-title":"Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation","volume":"16","author":"Elliott","year":"1982"},{"key":"b14","series-title":"J Infect Dis","first-page":"291","article-title":"Inactivation of Ebola virus with 60Co irradiation","volume":"143","author":"Lupton","year":"1981"},{"key":"b15","series-title":"J Med Virol","first-page":"341","article-title":"Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents","volume":"59","author":"Mahanty","year":"1999"},{"key":"b16","series-title":"Biologicals","first-page":"242","article-title":"Effect of gamma irradiation on the structural stability and functional activity of plasma-derived IgG","volume":"43","author":"Smeltzer","year":"2015"},{"key":"b17","series-title":"Vaccine","first-page":"1071","article-title":"The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated influenza A virus vaccine","volume":"35","author":"David","year":"2017"},{"key":"b18","series-title":"Viruses","first-page":"E204","article-title":"Inactivation of RNA viruses by gamma irradiation: a study on mitigating factors","volume":"8","author":"Hume","year":"2016"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/101\/1\/article-p207.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/101\/1\/article-p207.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/101\/1\/article-p207.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T14:46:58Z","timestamp":1722437218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/101\/1\/article-p207.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":18,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.19-0076","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,3]]}}}